Clinical significance of survivin expression in patients with urothelial carcinoma

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Chen, Hsin An ^a,b   Su, Chih Ming ^a,b   Hsieh, Hsiao Yen ^c   Tung, Chun Liang ^c   Hsu, Cheng Da ^c   Wang, Yuan Hung ^a,b   Shen, Cheng Huang ^c,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^d TAINAN UNIVERSITY OF TECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVIN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; UROTHELIAL CARCINOMA OF THE BLADDER; VERY ELDERLY; BLADDER TUMOR; DISEASE FREE SURVIVAL; EPITHELIUM; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

AGED; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; EPITHELIUM; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84896971490     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/574985     Document Type: Article

References (33)

1. Bureau of Health Promotion, Department of Health, Taiwan, Republic of China. Cancer registry annual report. 2012, http://www.hpa.gov.tw/BHPNet/Web/ Stat/Statistics.aspx
2. Wang Y.-H., Yeh S.-D., Shen K.-H., Shen C.-H., Juang G.-D., Hsu L.-I., Chiou H.-Y., Chen C.-J., A significantly joint effect between arsenic and occupational exposures and risk genotypes/diplotypes of CYP2E1, GSTO1 and GSTO2 on risk of urothelial carcinoma. Toxicology and Applied Pharmacology 2009 241 1 111 118 2-s2.0-70350010176 10.1016/j.taap.2009.08.008
3. Kakizoe T., Development and progression of urothelial carcinoma. Cancer Science 2006 97 9 821 828 2-s2.0-33746597351 10.1111/j.1349-7006.2006.00264.x
4. Kim W.-J., Bae S.-C., Molecular biomarkers in urothelial bladder cancer. Cancer Science 2008 99 4 646 652 2-s2.0-41349097718 10.1111/j.1349-7006.2008. 00735.x
5. Chiou S.-K., Jones M. K., Tarnawski A. S., Survivin-an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Medical Science Monitor 2003 9 4 PI25 PI29 2-s2.0-0037545607
6. Srivastava K., Srivastava A., Mittal B., Survivin promoter-31 G / C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Molecular Biology Reports 2012 39 2 1509 1516 2-s2.0-84859076418 10.1007/s11033-011-0889-9
7. Salvesen G. S., Duckett C. S., IAP proteins: blocking the road to death's door. Nature Reviews Molecular Cell Biology 2002 3 6 401 410 2-s2.0-0036088471 10.1038/nrm830
8. Akhtar M., Gallagher L., Rohan S., Survivin: role in diagnosis, prognosis, and treatment of bladder cancer. Advances in Anatomic Pathology 2006 13 3 122 126 2-s2.0-33747350845 10.1097/00125480-200605000-00003
9. Ambrosini G., Adida C., Altieri D. C., A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Medicine 1997 3 8 917 921 2-s2.0-0030746636 10.1038/nm0897-917
10. Sah N. K., Khan Z., Khan G. J., Bisen P. S., Structural, functional and therapeutic biology of survivin. Cancer Letters 2006 244 2 164 171 2-s2.0-33749256649 10.1016/j.canlet.2006.03.007
11. Xu Y., Fang F., Ludewig G., Jones G., Jones D., A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA and Cell Biology 2004 23 9 527 537 2-s2.0-4544260238 10.1089/1044549041939278
12. Wang Y.-H., Chiou H.-Y., Lin C.-T., Hsieh H.-Y., Wu C.-C., Hsu C.-D., Shen C.-H., Association between survivin gene promoter-31 C / G polymorphism and urothelial carcinoma risk in taiwanese population. Urology 2009 73 3 670 674 2-s2.0-60549114512 10.1016/j.urology.2008.09.048
13. Karam J. A., Lotan Y., Ashfaq R., Sagalowsky A. I., Shariat S. F., Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 2007 70 3 482 486 2-s2.0-34648843747 10.1016/j.urology.2007.05.009
14. Koike H., Sekine Y., Kamiya M., Nakazato H., Suzuki K., Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. Urology 2008 72 6 1229 1233 2-s2.0-56449095217 10.1016/j.urology.2007.12.064
15. Li X. B., Li S. N., Yang Z. H., Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population. DNA Cell Biology 2013 32 5 236 242
16. Huang L. N., Wang D. S., Chen Y. Q., Expression of survivin and patients survival in non-small cell lung cancer: a meta- analysis of the published studies. Molecular Biology Reports 2013 40 2 917 924
17. Srivastava A. K., Singh P. K., Srivastava K., Diagnostic role of survivin in urinary bladder cancer. Asian Pacific Journal of Cancer Prevention 2013 14 1 81 85
18. Ku J. H., Kwak C., Lee H. S., Park H. K., Lee E., Lee S. E., Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. Journal of Urology 2004 171 2 631 635 2-s2.0-0345868328 10.1097/01.ju.0000106082.44786.3b
19. Kitamura H., Torigoe T., Hirohashi Y., Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma. Virchows Archives 2013 462 1 101 107
20. Wu Y., Wang G., Wei J., Wen X., Survivin protein expression positively correlated with proliferative activity of cancer cells in bladder cancer. Indian Journal of Medical Sciences 2005 59 6 235 242 2-s2.0-21644450606
21. Yin W., Chen N., Zhang Y., Zeng H., Chen X., He Y., Wang X., Zhou Q., Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. Modern Pathology 2006 19 11 1487 1497 2-s2.0-33750300761 10.1038/modpathol.3800675
22. Pasin E., Josephson D. Y., Mitra A. P., Superfical bladder cancer: an update on etiology, molecular development, classification, and natural history. Reviews in Urology 2008 10 1 31 43
23. Blanc-Brude O. P., Mesri M., Wall N. R., Plescia J., Dohi T., Altieri D. C., Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clinical Cancer Research 2003 9 7 2683 2692 2-s2.0-0037817310
24. Altieri D. C., Survivin in apoptosis control and cell cycle regulation in cancer. Progress in Cell Cycle Research 2003 5 447 452 2-s2.0-0642317016
25. Qin Q., Zhang C., Zhu H., Association between survivin-31 G > C polymorphism and cancer risk: meta-analysis of 29 studies. Journal of Cancer Research and Clinical Oncology 2013 10.1007/s00432-013-1524-z
26. Wang X., Huang L., Xu Y., Shi Z., Wang Y., Zhang J., Wang X., Cao L., Luo H., Chen J., Liu N., Yin Y., You Y., Association between survivin-31 G < C promoter polymorphism and cancer risk: a meta-analysis. European Journal of Human Genetics 2012 20 790 795 2-s2.0-84856074129 10.1038/ejhg.2011.276
27. Weikert S., Christoph F., Schrader M., Krause H., Miller K., Müller M., Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. International Journal of Cancer 2005 116 1 100 104 2-s2.0-20444473184 10.1002/ijc.21000
28. Wang R., Morris D. S., Tomlins S. A., Lonigro R. J., Tsodikov A., Mehra R., Giordano T. J., Kunju L. P., Lee C. T., Weizer A. Z., Chinnaiyan A. M., Development of a multiplex quantitative PCR signature to predict progression In non-muscle-invasive bladder cancer. Cancer Research 2009 69 9 3810 3818 2-s2.0-65949085170 10.1158/0008-5472.CAN-08-4405
29. Shariat S. F., Karakiewicz P. I., Godoy G., Karam J. A., Ashfaq R., Fradet Y., Isbarn H., Montorsi F., Jeldres C., Bastian P. J., Nielsen M. E., Müller S. C., Sagalowsky A. I., Lotan Y., Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clinical Cancer Research 2009 15 22 7012 7019 2-s2.0-72549108606 10.1158/1078-0432.CCR-08-2554
30. Rödel F., Sprenger T., Kaina B., Survivin as a prognostic/predictive marker and molecular target in cancer therapy. Current Medicinal Chemistry 2012 19 22 3679 3688
31. Jeon C., Kim M., Kwak C., Kim H. H., Ku J. H., Prognostic role of survivin in bladder cancer: a systematic review and meta-analysis. PLoS ONE 2013 8 10 e76719
32. Lv S., Turlova E., Zhao S., Kang H., Han M., Sun H. S., Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis. Tumor Biology 2013 10.1007/s13277-013-1216-y
33. Lauss M., Ringnér M., Höglund M., Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: a validation study. Clinical Cancer Research 2010 16 17 4421 4433 2-s2.0-77956235993 10.1158/1078-0432.CCR-10-0606